These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 7939508

  • 1. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.
    Pekna M, Borowiec J, Fagerhol MK, Venge P, Thelin S.
    Scand J Thorac Cardiovasc Surg; 1994; 28(1):5-11. PubMed ID: 7939508
    [Abstract] [Full Text] [Related]

  • 2. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
    Fukutomi M, Kobayashi S, Niwaya K, Hamada Y, Kitamura S.
    Artif Organs; 1996 Jul; 20(7):767-76. PubMed ID: 8828766
    [Abstract] [Full Text] [Related]

  • 3. Complement activation during cardiopulmonary bypass: effects of immobilized heparin.
    Pekna M, Hagman L, Haldén E, Nilsson UR, Nilsson B, Thelin S.
    Ann Thorac Surg; 1994 Aug; 58(2):421-4. PubMed ID: 8067842
    [Abstract] [Full Text] [Related]

  • 4. Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.
    Horimoto H, Kondo K, Asada K, Sasaki S.
    Artif Organs; 1996 Aug; 20(8):936-40. PubMed ID: 8853810
    [Abstract] [Full Text] [Related]

  • 5. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes.
    Ovrum E, Mollnes TE, Fosse E, Holen EA, Tangen G, Ringdal MA, Videm V.
    Ann Thorac Surg; 1995 Dec; 60(6):1755-61. PubMed ID: 8787476
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass.
    Yamada H, Kudoh I, Hirose Y, Toyoshima M, Abe H, Kurahashi K.
    Acta Anaesthesiol Scand; 1996 Mar; 40(3):311-7. PubMed ID: 8721461
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass.
    Nishida H, Aomi S, Tomizawa Y, Endo M, Koyanagi H, Nojiri C, Oshiyama H, Kido T, Yokoyama K.
    Artif Organs; 1999 Jun; 23(6):547-51. PubMed ID: 10392283
    [Abstract] [Full Text] [Related]

  • 10. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
    Fosse E, Thelin S, Svennevig JL, Jansen P, Mollnes TE, Hack E, Venge P, Moen O, Brockmeier V, Dregelid E, Haldén E, Hagman L, Videm V, Pedersen T, Mohr B.
    Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
    [Abstract] [Full Text] [Related]

  • 11. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass.
    Hatori N, Yoshizu H, Haga Y, Kusama Y, Takeshima S, Segawa D, Tanaka S.
    Artif Organs; 1994 Dec; 18(12):904-10. PubMed ID: 7887827
    [Abstract] [Full Text] [Related]

  • 12. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery.
    Hoel TN, Videm V, Baksaas ST, Mollnes TE, Brosstad F, Svennevig JL.
    Perfusion; 2004 May; 19(3):177-84. PubMed ID: 15298426
    [Abstract] [Full Text] [Related]

  • 13. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M, Demircin M, Guvener M, Peker O, Yilmaz M.
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [Abstract] [Full Text] [Related]

  • 14. Heparin-coated bypass circuits reduce pulmonary injury.
    Redmond JM, Gillinov AM, Stuart RS, Zehr KJ, Winkelstein JA, Herskowitz A, Cameron DE, Baumgartner WA.
    Ann Thorac Surg; 1993 Sep; 56(3):474-8; discussion 479. PubMed ID: 8104392
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC, Ziats N, Rao AK, Gikakis N, Sun L, Khan MM, Stenach N, Sapatnekar S, Chouhan V, Gorman JH, Niewiarowski S, Colman RW, Anderson JM, Edmunds LH.
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: heparin-bonded versus nonbonded oxygenators.
    Ashraf S, Tian Y, Cowan D, Entress A, Martin PG, Watterson KG.
    Ann Thorac Surg; 1997 Dec; 64(6):1790-4. PubMed ID: 9436574
    [Abstract] [Full Text] [Related]

  • 20. Inflammatory system activation during cardiopulmonary bypass as an indicator of biocompatibility: a randomized comparison of bubble and membrane oxygenators.
    Nilsson L, Nilsson U, Venge P, Johansson O, Tydén H, Aberg T, Nyström SO.
    Scand J Thorac Cardiovasc Surg; 1990 Dec; 24(1):53-8. PubMed ID: 2353183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.